Clinical trial
An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
- Lead sponsor
- United Therapeutics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 21, 2018
- Completion date
- November 29, 2022
- Enrollment
- 41 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease, pulmonary hypertension